利拉鲁肽
奥利斯特
医学
减肥
不利影响
肥胖
内科学
持久性(不连续性)
胃肠病学
内分泌学
2型糖尿病
糖尿病
岩土工程
工程类
作者
Luis Fernando Valladales‐Restrepo,Nicolás Sánchez-Ramírez,Andrés Felipe Usma-Valencia,Andrés Gaviria‐Mendoza,Manuel Enrique Machado‐Duque,Jorge Enrique Machado‐Alba
标识
DOI:10.1080/14656566.2023.2178900
摘要
To determine the effectiveness, persistence of use, adverse reactions, interactions of orlistat and liraglutide taken for weight loss by a group of obese patients in Colombia.A retrospective follow-up study of a cohort of patients with obesity treated with orlistat or liraglutide. Sociodemographic, clinical, and pharmacological variables were identified. The effectiveness for weight loss at 12-16 and 52 weeks, persistence of use, and safety were determined.A total of 294 patients were followed up. At 12-16 weeks after starting orlistat and liraglutide, weight losses of -1.2kg (p=0.002) and -4.1kg (p<0.001) were observed, respectively, and at 52 weeks, reductions of -1.6kg (p=0.208) and -7.8kg (p<0.001) were observed. A total of 8.8% and 31.3% of patients treated with orlistat and liraglutide, respectively, persisted with treatment 1 year after initiation. A total of 17.3% had adverse drug reactions. Older adults with grade II or III obesity who performed physical activity and those treated with liraglutide were more likely to have lost at least 5% of their body weight at 12-16 weeks.Orlistat and liraglutide users presented weight loss at 12-16 weeks. However, this effect was greater and sustained with liraglutide, especially when combined with physical activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI